Therapeutics

Top Story

BLOG: When costly drugs are standard of care

February 10, 2017

Let’s say you’re going to the hardware store to buy a wrench. Naturally, the store sells more than one product that can do the same job, but let’s pretend that one wrench is, say, 10% better than another. Maybe it requires 10% less effort to turn the bolt or maybe it turns the bolt 10% tighter. How much more would you pay for that wrench?

Some of us would choose the less expensive wrench regardless of price, figuring that either product gets the job done, so why not save a little? Some might spring for the better tool regardless of price, always wanting to “own the best.” Most of us, though, would consider the price difference in relation to how much we expect to use the wrench, and we’ll judge whether the price differential is worth it.

Nicox to study NCX 470 for lowering IOP

January 31, 2017
Nicox is finalizing the design of a first-in-human trial for NCX 470, its novel nitric oxide donating bimatoprost analog being developed for intraocular pressure…
Perspectives on Glaucoma

Fixed combination may improve compliance over unfixed therapy

January 19, 2017
Fixed combination travoprost 0.004%-timolol 0.5% may promote improved adherence compared with separate containers of travoprost 0.004% and timolol 0.5% in patients with…

European Commission grants orphan drug designation to oculopharyngeal muscular dystrophy treatment

January 18, 2017
After a positive recommendation from the European Medicines Agency, the European Commission has granted orphan drug designation to BB-301, an investigational therapy for…
COPE

Diabetic Eye Disease: Screening Strategies and Imaging Devices - Number 1

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Video

VIDEO: Consider systemic factors when prescribing orals

December 1, 2015
More »
Featured
Video
Meeting News Coverage

VIDEO: Gonzalez: Point-of-care testing helps personalize care

July 1, 2015
More »

BLOG: When costly drugs are standard of care

February 10, 2017
Let’s say you’re going to the hardware store to buy a wrench. Naturally, the store sells more than one product that can do the same job…

Nicox to study NCX 470 for lowering IOP

January 31, 2017
Nicox is finalizing the design of a first-in-human trial for NCX 470, its novel nitric oxide donating bimatoprost analog being developed for…

Perspectives on Glaucoma

Fixed combination may improve compliance over unfixed therapy

January 19, 2017
Fixed combination travoprost 0.004%-timolol 0.5% may promote improved adherence compared with separate containers of travoprost 0.004% and timolol…

European Commission grants orphan drug designation to oculopharyngeal muscular dystrophy treatment

January 18, 2017
After a positive recommendation from the European Medicines Agency, the European Commission has granted orphan drug designation to BB-301, an…

Blog

BLOG: ‘Doc, can I take this drug if I have glaucoma?’

January 4, 2017
In the mid-1990s, the FDA relaxed regulations regarding direct-to-consumer pharmaceutical advertising that brought ads for medications from the…

In the Journals

Povidone-iodine promising for bacterial keratitis in developing world

December 30, 2016
Povidone-iodine 1.25% can be considered for the treatment of bacterial keratitis when antibiotic treatment is not practical, according to researchers…

Promising phase 3 results for giant cell arteritis treatment

December 12, 2016
Genentech announced positive results from the phase 3 trial, GiACTA, which evaluated Actemra in people with giant cell arteritis, according to a…

BioLine, Novartis license dry eye agent

December 8, 2016
BioLineRx Ltd. signed an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. for the…

Perspectives on Glaucoma

Rate of visual field progression similar for trabeculectomy, topical therapy

December 1, 2016
Most patients after trabeculectomy demonstrate relatively slow rates of visual field progression, similar to those treated medically, according to…

Perspectives on GlaucomaPerspective

Study does not support field improvement after IOP-reducing therapy

November 29, 2016
In a study from Investigative Ophthalmology & Vision Science, researchers were unable to draw any association between therapeutic lowering of…

More Headlines »
Advertisement
Advertisement